HKEX Stock Code: 01093English|繁體|简体
Home > Investor Relations > Announcements & Notices
Announcements & Notices
Jul
31
VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SYS6041 AS A COMBINATION THERAPY FOR THE TREATMENT OF RECURRENT OVARIAN CANCER OFFICIALLY INITIATED AT THE FIRST CENTRE IN CHINA
Jul
31
VOLUNTARY ANNOUNCEMENT - RECOMBINANT RESPIRATORY SYNCYTIAL VIRUS VACCINE (SYS6057) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Jul
30
DISCLOSEABLE TRANSACTION - ENTERING INTO OF (1) FX SWAP CONTRACT AND (2) FX FORWARD CONTRACTS
Jul
29
VOLUNTARY ANNOUNCEMENT - CRB-701 (SYS6002) RECEIVES U.S. FDA CLEARANCE FOR THE REGISTRATIONAL TRIAL FOR THE SECOND-LINE TREATMENT OF OROPHARYNGEAL CANCER
Jul
29
VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SYH2062 INJECTION FOR THE TREATMENT OF ADULT ESSENTIAL HYPERTENSION OFFICIALLY INITIATED AT THE FIRST CENTRE IN CHINA
Jul
27
VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION FOR SIROLIMUS FOR INJECTION (ALBUMIN-BOUND) ACCEPTED BY THE NMPA
Jul
27
VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL TRIAL OF AMMOXETINE HYDROCHLORIDE ENTERIC-COATED TABLETS (HA1406) FOR THE TREATMENT OF PATIENTS WITH DEPRESSION MET THE PRIMARY ENDPOINT
Jul
27
INDICATIVE RESULTS OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE SIX MONTHS ENDED 30 JUNE 2026
Jul
27
POSITIVE PROFIT ALERT
Jul
24
VOLUNTARY ANNOUNCEMENT - PALIPERIDONE PALMITATE INJECTION RECEIVES MARKETING APPROVAL
Jul
22
VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SYS6026 INJECTION FOR THE TREATMENT OF HPV TYPE 16- OR 18-RELATED CERVICAL HIGH-GRADE SQUAMOUS INTRAEPITHELIAL LESION OFFICIALLY INITIATED IN CHINA
Jul
17
VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION FOR TRASTUZUMAB ENVEDOTIN INJECTION ACCEPTED BY THE NMPA
Jul
16
VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SIROLIMUS FOR INJECTION (ALBUMIN-BOUND) FOR THE TREATMENT OF EPITHELIOID HAEMANGIOENDOTHELIOMA OFFICIALLY INITIATED AT THE FIRST CENTRE IN CHINA
Jul
16
VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL TRIAL OF SYS6043 FOR THE TREATMENT OF PLATINUM-RESISTANT ADVANCED OVARIAN CANCER, PRIMARY PERITONEAL CANCER, AND FALLOPIAN TUBE CANCER OFFICIALLY INITIATED AT THE FIRST CENTRE IN CHINA
Jul
14
VOLUNTARY ANNOUNCEMENT - DOCETAXEL FOR INJECTION (ALBUMIN-BOUND) (HB1801) AND ANBENITAMAB (KN026) GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR THE FIRST-LINE TREATMENT OF ADVANCED HER2-POSITIVE BREAST CANCER
Jul
10
VOLUNTARY ANNOUNCEMENT - RECEIPT OF US$25 MILLION RESEARCH AND DEVELOPMENT MILESTONE PAYMENT UNDER THE STRATEGIC COLLABORATION AND LICENSE AGREEMENT WITH ASTRAZENECA
Jul
07
VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SYH2070 INJECTION FOR THE TREATMENT OF MIXED HYPERLIPIDAEMIA OFFICIALLY INITIATED AT THE FIRST CENTRE IN CHINA
Jul
02
VOLUNTARY ANNOUNCEMENT - SYS6043 GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR THE TREATMENT OF PLATINUM-RESISTANT OVARIAN CANCER, PRIMARY PERITONEAL CARCINOMA AND FALLOPIAN TUBE CANCER
Jul
02
VOLUNTARY ANNOUNCEMENT - IRON SUCROSE INJECTION RECEIVES MARKETING APPROVAL
Jul
02
VOLUNTARY ANNOUNCEMENT - RECOMBINANT HERPES ZOSTER VACCINE (SYS6052) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Jul
02
VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL STUDY OF SYH2095 TABLETS AS A MONOTHERAPY OR IN COMBINATION REGIMENS FOR THE TREATMENT OF ADVANCED MALIGNANT TUMOURS OFFICIALLY INITIATED IN CHINA
Jul
02
VOLUNTARY ANNOUNCEMENT - ENTERING INTO COLLABORATION, OPTION AND LICENSE AGREEMENT WITH ASTRAZENECA FOR THE DEVELOPMENT OF siRNA DRUGS
Jun
30
VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL TRIAL OF SYS6010 IN COMBINATION WITH ENLONSTOBART FOR THE ADJUVANT TREATMENT OF RESECTED STAGE II-IIIB NON-SMALL CELL LUNG CANCER WITH ACTIONABLE GENOMIC ALTERATION-NEGATIVE STATUS AND WITHOUT ACHIEVING MPR OFFICIALLY INITIATED IN CHINA
Jun
26
VOLUNTARY ANNOUNCEMENT - ON-MARKET PURCHASE OF SHARES PURSUANT TO THE 2026 SHARE AWARD SCHEME
Jun
26
VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL STUDY OF SYS6010 IN COMBINATION WITH ENLONSTOBART FOR THE TREATMENT OF DRIVER GENE-NEGATIVE NON-SMALL CELL LUNG CANCER OFFICIALLY INITIATED IN CHINA
Jun
25
VOLUNTARY ANNOUNCEMENT - ON-MARKET PURCHASE OF SHARES PURSUANT TO THE 2026 SHARE AWARD SCHEME
Jun
23
VOLUNTARY ANNOUNCEMENT - ON-MARKET PURCHASE OF SHARES PURSUANT TO THE 2026 SHARE AWARD SCHEME
Jun
22
VOLUNTARY ANNOUNCEMENT - ON-MARKET PURCHASE OF SHARES PURSUANT TO THE 2026 SHARE AWARD SCHEME
Jun
22
FURTHER ANNOUNCEMENT - UPDATE ON DISCLOSEABLE TRANSACTION IN RELATION TO THE PROPOSED H SHARE LISTING OF CSPC INNOVATION
Jun
18
VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTS SECOND MARKETING AUTHORISATION APPLICATION FOR EFMEDAGLUTIDE ALFA INJECTION
Jun
18
VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTS MARKETING AUTHORISATION APPLICATION FOR SECUKINUMAB INJECTION
Jun
18
VOLUNTARY ANNOUNCEMENT - OCTREOTIDE LONG-ACTING INJECTION (SYHX2008) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Jun
17
VOLUNTARY ANNOUNCEMENT - ON-MARKET PURCHASE OF SHARES PURSUANT TO THE 2026 SHARE AWARD SCHEME
Jun
16
VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTS MARKETING AUTHORISATION APPLICATION FOR VALSARTAN AND LEVAMLODIPINE MALEATE TABLETS (SYH9056 TABLETS)
Jun
16
VOLUNTARY ANNOUNCEMENT - ON-MARKET PURCHASE OF SHARES PURSUANT TO THE 2026 SHARE AWARD SCHEME
Jun
15
VOLUNTARY ANNOUNCEMENT - PACLITAXEL FOR INJECTION (ALBUMIN-BOUND) (II) RECEIVES MARKETING APPROVAL
Jun
10
VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL STUDY OF ANBENITAMAB (KN026) IN COMBINATION WITH DOCETAXEL FOR INJECTION (ALBUMIN-BOUND) (HB1801) FOR FIRST-LINE TREATMENT OF HER2-POSITIVE ADVANCED BREAST CANCER MEETS PRIMARY ENDPOINT
Jun
09
VOLUNTARY ANNOUNCEMENT - ON-MARKET PURCHASE OF SHARES PURSUANT TO THE 2026 SHARE AWARD SCHEME
Jun
08
VOLUNTARY ANNOUNCEMENT - ON-MARKET PURCHASE OF SHARES PURSUANT TO THE 2026 SHARE AWARD SCHEME
Jun
08
VOLUNTARY ANNOUNCEMENT - SEMAGLUTIDE LONG-ACTING INJECTION (SYH9017) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Jun
08
VOLUNTARY ANNOUNCEMENT - GRANT OF AWARDED SHARES PURSUANT TO THE 2018 SHARE AWARD SCHEME
Jun
05
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Jun
05
RESIGNATION OF EXECUTIVE DIRECTOR
Jun
03
VOLUNTARY ANNOUNCEMENT - ON-MARKET PURCHASE OF SHARES PURSUANT TO THE 2026 SHARE AWARD SCHEME
Jun
02
VOLUNTARY ANNOUNCEMENT - FIRST mRNA-LNP-BASED DUAL-TARGET CAR-T CELL INJECTION (SYS6063 INJECTION) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Jun
02
VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL STUDY DATA OF NOVEL B7-H3 ANTIBODY-DRUG CONJUGATE SYS6043 PRESENTED IN AN ORAL SESSION AT THE 2026 ASCO ANNUAL MEETING
Jun
01
PHASE III CLINICAL STUDY RESULTS OF ANBENITAMAB (KN026) IN COMBINATION WITH DOCETAXEL FOR INJECTION (ALBUMIN-BOUND) (HB1801) FOR NEOADJUVANT TREATMENT OF HER2-POSITIVE BREAST CANCER SELECTED FOR LBA ORAL PRESENTATION AT THE 2026 ASCO ANNUAL MEETING
May
29
RECEIPT OF US$1.2 BILLION UPFRONT PAYMENT UNDER THE STRATEGIC COLLABORATION AND LICENSE AGREEMENT WITH ASTRAZENECA FOR THE DEVELOPMENT OF INNOVATIVE LONG-ACTING PEPTIDE MEDICINES
May
29
ENNITUO (ANBENITAMAB INJECTION) RECEIVES MARKETING AUTHORISATION FROM NMPA
May
28
POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 28 MAY 2026
May
28
ARTICLES OF ASSOCIATION
May
27
QUARTERLY RESULTS FOR THE THREE MONTHS ENDED 31 MARCH 2026
May
26
VOLUNTARY ANNOUNCEMENT - LANSOPRAZOLE ENTERIC-COATED CAPSULES OBTAIN DRUG REGISTRATION APPROVAL
May
22
VOLUNTARY ANNOUNCEMENT - USTEKINUMAB INJECTION RECEIVES MARKETING AUTHORISATION FROM NMPA
May
21
VOLUNTARY ANNOUNCEMENT - BUDESONIDE ENTERIC-COATED CAPSULES OBTAIN DRUG REGISTRATION APPROVAL
May
18
VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE KAT6 INHIBITOR (SYH2095 TABLETS) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
May
14
DATE OF BOARD MEETING
May
11
VOLUNTARY ANNOUNCEMENT - SYS6010 GRANTED ANOTHER BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Apr
29
VOLUNTARY ANNOUNCEMENT - MARKETING AUTHORISATION APPLICATION FOR AMPHOTERICIN B LIPOSOMAL, POWDER FOR CONCENTRATE FOR DISPERSION FOR INFUSION (HC1507G2) APPROVED IN EUROPE
Apr
29
VOLUNTARY ANNOUNCEMENT - SYS6051 OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Apr
28
NOTICE OF ANNUAL GENERAL MEETING
Apr
27
UNAUDITED FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE THREE MONTHS ENDED 31 MARCH 2026
Apr
24
VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE KAT6 INHIBITOR (SYH2059 TABLETS) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Apr
20
PROPOSED AMENDMENTS TO THE EXISTING ARTICLES OF ASSOCIATION AND ADOPTION OF THE NEW ARTICLES OF ASSOCIATION
Apr
20
VOLUNTARY ANNOUNCEMENT - Phase Ib/III Clinical Study of Sirolimus for Injection (Albumin-Bound) (HB1901) for the Treatment of Advanced Malignant Perivascular Epithelioid Cell Tumour (PEComa) Meets Primary Endpoint
Apr
15
VOLUNTARY ANNOUNCEMENT - SYS6051 OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Apr
08
UPDATE ANNOUNCEMENT - CONNECTED TRANSACTION IN RELATION TO THE DISPOSAL OF 30.0704% EQUITY INTEREST IN THE TARGET COMPANY
Apr
02
VOLUNTARY ANNOUNCEMENT - GRANT OF AWARDED SHARES PURSUANT TO THE 2018 SHARE AWARD SCHEME OF THE COMPANY
Mar
31
VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL STUDY OF ANBENITAMAB (KN026) IN COMBINATION WITH DOCETAXEL (ALBUMIN-BOUND) (HB1801) FOR NEOADJUVANT TREATMENT OF HER2+ BREAST CANCER MEETS PRIMARY ENDPOINT
Mar
25
VOLUNTARY ANNOUNCEMENT - ADOPTION OF THE 2026 SHARE AWARD SCHEME
Mar
25
CASH DIVIDEND ANNOUNCEMENT FOR EQUITY ISSUER
Mar
25
ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2025
Mar
23
VOLUNTARY ANNOUNCEMENT - APREPITANT INJECTION OBTAINS DRUG REGISTRATION APPROVAL
Mar
20
VOLUNTARY ANNOUNCEMENT - GLP-1/GIP RECEPTOR DUAL-BIASED AGONIST POLYPEPTIDE LONG-ACTING INJECTION (SYH2082 INJECTION) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Mar
16
FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE YEAR ENDED 31 DECEMBER 2025
Mar
16
VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE PDE4B INHIBITOR (SYH2059 POWDER FOR INHALATION) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Mar
13
DATE OF BOARD MEETING
Mar
06
VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE PDE4B INHIBITOR (SYH2059 POWDER FOR INHALATION) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Mar
05
VOLUNTARY ANNOUNCEMENT - INDACATEROL ACETATE AND MOMETASONE FUROATE POWDER FOR INHALATION OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Mar
04
VOLUNTARY ANNOUNCEMENT - EMICIZUMAB INJECTION (SYS6053) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Mar
02
VOLUNTARY ANNOUNCEMENT - PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION, RAPID SUSPENSION (ALBUMIN-BOUND) (SYHX2011G1) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Mar
02
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
Mar
02
APPOINTMENT OF AN EXECUTIVE DIRECTOR
Feb
26
CONNECTED TRANSACTION - DISPOSAL OF 30.0704% EQUITY INTEREST IN THE TARGET COMPANY
Feb
16
VOLUNTARY ANNOUNCEMENT - GLP-1/GIP RECEPTOR DUAL-BIASED AGONIST POLYPEPTIDE LONG-ACTING INJECTION (SYH2082 INJECTION) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Feb
16
VOLUNTARY ANNOUNCEMENT - ROPIVACAINE LONG-ACTING INJECTION (SYH9089 INJECTION) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Feb
02
VOLUNTARY ANNOUNCEMENT - CLEVIDIPINE INJECTABLE EMULSION OBTAINS DRUG REGISTRATION APPROVAL
Jan
30
VOLUNTARY ANNOUNCEMENT - ENTERING INTO A STRATEGIC COLLABORATION AND LICENSE AGREEMENT WITH ASTRAZENECA FOR THE DEVELOPMENT OF INNOVATIVE LONG-ACTING PEPTIDE MEDICINES
Jan
29
VOLUNTARY ANNOUNCEMENT - SYS6055 INJECTION OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Jan
23
VOLUNTARY ANNOUNCEMENT - GRANT OF AWARDED SHARES PURSUANT TO THE SHARE AWARD SCHEME OF THE COMPANY
Jan
15
INDICATIVE RESULTS OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE YEAR ENDED 31 DECEMBER 2025
Jan
13
VOLUNTARY ANNOUNCEMENT - POTENT ALDOSTERONE SYNTHASE INHIBITOR (SYH2072 TABLETS) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Jan
12
VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTS MARKETING AUTHORISATION APPLICATION FOR PRUSOGLIPTIN AND METFORMIN EXTENDED-RELEASE TABLETS
Jan
02
VOLUNTARY ANNOUNCEMENT - NINTEDANIB ESILATE POWDER FOR INHALATION OBTAINS CLINICAL TRIAL APPROVAL IN CHINA

Please download the latest "Acrobat Reader" to view the PDF.

© Copyright 2026 CSPC Pharmaceutical Group Limited. All Rights Reserved.
Disclaimer